Avalo Therapeutics Financial Ratios
NASDAQ: AVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
13.65+0.22 (+1.64%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Avalo Therapeutics ratio analysis
Avalo Therapeutics earned a net margin of -132642.4% in FY 2025, down from -7965.8% a year earlier. Return on equity reached -94.2%, meaning Avalo Therapeutics generated -0.94 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Avalo Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | — | — | — | — | — | — | — | — | 21,942.86 | — |
| Price / sales | 3,866.95 | 84.21 | 1.31 | 2.63 | — | — | — | 49,871.82 | 6,100.23 | 19,410.24 |
| Price / book | 2.75 | 0.28 | 0.35 | — | — | — | — | 16,764.98 | 6,090.06 | 108,113.71 |
| Gross margin | — | — | 33.3% | 81.0% | 72.4% | 95.5% | 108.4% | 53.6% | 97.7% | 100.0% |
| Operating margin | -123,601.7% | -15,535.6% | -1,421.6% | -207.4% | -1,521.6% | -1,087.4% | -239.1% | -503.4% | 49.9% | -1,394.6% |
| Net margin | -132,642.4% | -7,965.8% | -1,639.5% | -230.8% | -1,563.1% | -947.9% | -238.1% | -569.9% | 42.7% | -1,428.6% |
| Free cash flow margin | -87,216.9% | -11,123.8% | -1,602.8% | -148.7% | -1,315.4% | -606.1% | -287.3% | -52.5% | 45.1% | -1,267.0% |
| Return on equity (ROE) | -94.2% | -26.4% | -431.9% | — | -365.5% | -258.5% | -76.6% | -191.6% | 42.6% | -7,957.2% |
| Return on assets (ROA) | -67.2% | -23.3% | -150.3% | -124.8% | -105.2% | -145.1% | -44.5% | -57.0% | 27.7% | -285.5% |
| Debt / equity | — | — | 0.00 | — | 1.42 | 0.00 | — | 0.74 | 0.00 | 11.37 |
| Current ratio | 8.14 | 19.96 | 1.82 | 0.74 | 3.11 | 1.71 | 1.46 | 0.84 | 0.96 | 1.31 |
| Revenue growth | -86.6% | -77.1% | -89.3% | 234.4% | -19.4% | -0.8% | -4.0% | -74.7% | 2,312.3% | — |
| EPS growth | — | — | — | — | — | — | — | -385.7% | — | — |